CANCER PROGRESS 2020 PANELS:

  • Paradigm-shifting platforms I, IO: Taking IO to the next Level
  • Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable
  • Investing into Oncology: Who, What and Where?
  • Vaccines: From Paleo to Neo, Cancer Vaccines in the New Age of IO
  • Next Wave of Diagnostics, Including Precision IO: Early and Smarter, the Better to Cure
  • Inflecting Value in Early Stage Biotech ( in an Increasingly Cost Conscious Environment): Linking Proof of Relevance to Pricing & Reimbursement

AND INTRODUCING: ADVANCED THERAPEUTICS – ½ DAY SESSION

  • Antigen/platform pairings (“Forget Wine and Cheese…Get this Right and Your Valuation Takes Flight”)
  • State of the union for off-the-shelf (“In an ‘Allo or Bust’ Market, What’s Rising to the Top of the Shelf?”)
  • What are investors and partners looking for today (“How to Stand Out/Inflect Value in a Frothy Vat of Cells”)

Keynote Speaker

Michael A. Curran, PhD

Michael A. Curran, PhD
Associate Professor, Dept. of Immunology Scientific Director
ORBIT Platform,The University of Texas MD Anderson Cancer Center
Department of Immunology, Division of Basic Sciences

Thank You to our 2020 Sponsors and Supporters




Venue

Convene at 32 Old Slip
32 Old Slip, New York, NY 10005 | 1.888.730.7307
http://convene.com/location/financial-district-downtown-nyc/

Testimonials

“I truly enjoyed the conference. I told several colleagues and friends that this has been one of the best conferences I have ever attended.”

Christoph Lengauer, Chief Scientific Officer

Blueprint Medicines

“What an unbelievable 2-day event that was. The intimate atmosphere (I made great new contacts) and dynamic (sometimes “dynamic tension”) interaction between panel members was fantastic. I kept great notes and have already shared the very enthusiastic feedback & takeaways with my management team.”

Armand Girard, Vice President, Corporate Development

GlycoMimetics

“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa

Novartis

“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company